drugset
Drugs / GSK3117391
last change Nov 2017 re-read 3 minutes ago

GSK3117391

also known as CHR-5154 · CYCLOHEXANEACETIC ACID, .ALPHA.-(((6-(3-(HYDROXYAMINO)-3-OXOPROPYL)-3-PYRIDINYL)METHYL)AMINO)-, CYCLOPENTYL ESTER, (.ALPHA.S)- · Hdac-in-3

Small molecule

Developed for
rheumatoid arthritis
Investigated by
GlaxoSmithKline

Trials 2

today NCT02965599 · Ph 2 NCT01934101 · Ph 1
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01934101 Aug 2013 → May 2014 rheumatoid arthritis GlaxoSmithKline Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT02965599 Dec 2016 → Nov 2017 rheumatoid arthritis GlaxoSmithKline Terminated No outcome recorded Stop: Business

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as GSK3117391 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02965599 ↗
Known as CHR-5154 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01934101 ↗
Known as CYCLOHEXANEACETIC ACID, .ALPHA.-(((6-(3-(HYDROXYAMINO)-3-OXOPROPYL)-3-PYRIDINYL)METHYL)AMINO)-, CYCLOPENTYL ESTER, (.ALPHA.S)- ChEMBL registry synonym — accepted as the source's own label CHEMBL4297494 ↗
Known as Hdac-in-3 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297494 ↗
Modality Small molecule — CHEMBL4297494 ↗
Route Oral “single and multiple oral doses of CHR-5154” NCT01934101 ↗